{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:47:45Z","timestamp":1788965265110,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Malignant pleural mesothelioma (MPM) is a rare type of tumor closely associated with asbestos exposure. Increasing evidence shows that high immuno-heterogeneity reduces the therapeutic efficacy of MPM. At present, good biomarkers to screen immunodominant populations and predict the efficacy of immunotherapy are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, expression data from TCGA, GSE2459, GSE51024, and GSE29354 were integrated for model construction. An eight-gene risk score model (FLI1, IL32, FUCA1, CCR2, PSMB10, CCL5, WT1, and KRT5) was constructed using CIBERSORT, weighted gene co-expression network analysis, Cox regression analysis, differentially expressed gene analysis, and protein\u2013protein interaction network. The K\u2013M survival analysis was used to evaluate the prediction ability of the risk score model. The TIDE database and Oncology Drug Sensitivity Genomics database were used to assess the predictive power of risk score models for treatment. In addition, the expression of the key gene in para-carcinoma tissue and MPM samples were detected by Immunohistochemistry. Patient clinical information was employed to evaluate the relationship between key genes and patient survival. Finally, the biological functions of the key gene were examined by in vitro and in vivo experiments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The score model was used to divide patients with MPM into low- and high-risk groups. The high-risk group was characterized by a survival disadvantage, and they were less sensitive to immunotherapy. Clinical data suggest that FUCA1, which is a key gene in the model, is an independent risk factor for predicting the prognosis of patients with MPM. A series of experiments demonstrated that FUCA1 expression was negatively correlated with the proliferation, invasion and migration abilities of MPM cells. Further studies revealed that FUCA1 inhibited epithelial\u2013mesenchymal transition in MPM cells by regulating the PI3K-AKT signaling pathway.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The risk score model provides a new perspective for screening potential populations to benefit from immunotherapy and predicting their survival. FUCA1 may be a potential prognostic biomarker and promising therapeutic target for patients with MPM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1577232","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:28:40Z","timestamp":1747978120000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune-related gene risk model establishment and role of key gene FUCA1 in malignant pleural mesothelioma"],"prefix":"10.3389","volume":"16","author":[{"given":"Lin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingzhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1003-S1007","DOI":"10.21037\/jtd.2018.04.31","article-title":"Biomarkers in malignant pleural mesothelioma: current status and future directions","volume":"10","author":"Ahmadzada","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investigation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet London, Engl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/gcc.22670","article-title":"Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes","volume":"57","author":"Betti","year":"2018","journal-title":"Genes, Chromosomes and Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1158\/1078-0432.CCR-16-0066","article-title":"Genomic approaches to understanding response and resistance to immunotherapy","volume":"22","author":"Braun","year":"2016","journal-title":"Clin. Cancer Res. Official J. Am. Assoc. For Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignant peritoneal mesothelioma: a review","volume":"7","author":"Broeckx","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.08.011","article-title":"The resistance related to targeted therapy in malignant pleural mesothelioma: why has not the target been hit yet?","volume":"107","author":"Bronte","year":"2016","journal-title":"Crit. Rev. Oncology\/hematology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"21283","DOI":"10.18632\/oncotarget.4238","article-title":"Down-regulation of \u03b1-L-fucosidase 1 expression confers inferior survival for triple-negative breast cancer patients by modulating the glycosylation status of the tumor cell surface","volume":"6","author":"Cheng","year":"2015","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"102815","DOI":"10.1016\/j.critrevonc.2019.102815","article-title":"Emerging therapies in malignant pleural mesothelioma","volume":"144","author":"Cinausero","year":"2019","journal-title":"Crit. Rev. Oncology\/hematology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12967-019-2100-3","article-title":"The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort","volume":"17","author":"Damotte","year":"2019","journal-title":"J. Transl. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/2159-8290.CD-20-0603","article-title":"Direct and indirect regulators of epithelial-mesenchymal transition-mediated immunosuppression in breast carcinomas","volume":"11","author":"Dongre","year":"2021","journal-title":"Cancer Discov."},{"key":"B12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin. Cancer Res. Official J. Am. Assoc. For Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/cas.12933","article-title":"Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells","volume":"107","author":"Ezawa","year":"2016","journal-title":"Cancer Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00262-018-2150-z","article-title":"Quantifying tumor-infiltrating immune cells from transcriptomics data","volume":"67","author":"Finotello","year":"2018","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/s41591-019-0645-6","article-title":"Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer","volume":"25","author":"Ghatalia","year":"2019","journal-title":"Nat. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"20073","DOI":"10.3390\/molecules191220073","article-title":"Alteration of N-glycans and expression of their related glycogenes in the epithelial-mesenchymal transition of HCV29 bladder epithelial cells","volume":"19","author":"Guo","year":"2014","journal-title":"Mol. Basel, Switz."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.3390\/cancers16152753","article-title":"FUCA1: an underexplored p53 target gene linking glycosylation and cancer progression","volume":"16","author":"Hu","year":"2024","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.gene.2006.11.002","article-title":"Comparative and phylogenetic analysis of alpha-L-fucosidase genes","volume":"392","author":"Intra","year":"2007","journal-title":"Gene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3389\/fimmu.2015.00516","article-title":"Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy","volume":"6","author":"Kersten","year":"2015","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinforma."},{"key":"B21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1200\/JCO.2010.30.5425","article-title":"Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction","volume":"29","author":"Mlecnik","year":"2011","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"B24","doi-asserted-by":"publisher","first-page":"16986","DOI":"10.3390\/ijms140816986","article-title":"Decreased expression of alpha-L-fucosidase gene FUCA1 in human colorectal tumors","volume":"14","author":"Otero-Est\u00e9vez","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet London, Engl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/mco.2022.2522","article-title":"Novel approaches for the treatment of unresectable malignant pleural mesothelioma: a focus on immunotherapy and target therapy (Review)","volume":"16","author":"Rijavec","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial-mesenchymal transitions in tumour progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3892\/ijo.2017.3968","article-title":"FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status","volume":"50","author":"Tsuchida","year":"2017","journal-title":"Int. J. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1016\/j.cllc.2018.08.007","article-title":"Survival by histologic subtype of malignant pleural mesothelioma and the impact of surgical resection on overall survival","volume":"19","author":"Verma","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"106477","DOI":"10.1016\/j.intimp.2020.106477","article-title":"Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures","volume":"83","author":"Wu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1111\/cas.14427","article-title":"Downregulation of \u03b1-l-fucosidase 1 suppresses glioma progression by enhancing autophagy and inhibiting macrophage infiltration","volume":"111","author":"Xu","year":"2020","journal-title":"Cancer Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"B39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13046-024-03048-1","article-title":"Tumor-suppressive miR-4732-3p is sorted into fucosylated exosome by hnRNPK to avoid the inhibition of lung cancer progression","volume":"43","author":"Zhuang","year":"2024","journal-title":"J. Exp. and Clin. Cancer Res. CR"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1577232\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:28:42Z","timestamp":1747978122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1577232\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":39,"alternative-id":["10.3389\/fphar.2025.1577232"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1577232","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"article-number":"1577232"}}